Zeltiq Aesthetics Receives Average Rating of “Buy” from Analysts (NASDAQ:ZLTQ)
Zeltiq Aesthetics (NASDAQ:ZLTQ) has been given an average recommendation of “Buy” by the eight ratings firms that are currently covering the company, AnalystRatings.NET reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $24.26.
Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 20.13 on Wednesday. Zeltiq Aesthetics has a one year low of $6.67 and a one year high of $24.79. The stock has a 50-day moving average of $16.07 and a 200-day moving average of $17.84. The company’s market cap is $755.4 million.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.20. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $34.93 million. The company’s revenue for the quarter was up 79.1% on a year-over-year basis. On average, analysts predict that Zeltiq Aesthetics will post $-0.18 earnings per share for the current fiscal year.
In other Zeltiq Aesthetics news, Director Jean George unloaded 29,157 shares of the stock on the open market in a transaction dated Thursday, July 31st. The shares were sold at an average price of $20.09, for a total value of $585,764.13. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
ZLTQ has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Zeltiq Aesthetics from $26.00 to $27.00 in a research note on Thursday. Separately, analysts at Maxim Group raised their price target on shares of Zeltiq Aesthetics from $25.00 to $30.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “positive” rating on shares of Zeltiq Aesthetics in a research note on Monday, May 5th.
Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.